Precision Neuroscience's goal is to provide breakthrough treatments for the one billion people worldwide suffering from neurological illnesses. We are building the only brain-computer interface that is designed to be minimally invasive, safely removable, and capable of processing large amounts of data.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/26/23 | $41,000,000 | Series B |
Alumni Ventures Group B Capital Group Draper Associates Forepont Capital Partners  Mubadala Capital re.Mind Capital Steadview Capital | undisclosed |
| 12/16/24 | $102,000,000 | Series C |
B Capital Duquesne Family Office General Equity Holdings Steadview Capital | undisclosed |
